CL2019001522A1 - Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal. - Google Patents
Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal.Info
- Publication number
- CL2019001522A1 CL2019001522A1 CL2019001522A CL2019001522A CL2019001522A1 CL 2019001522 A1 CL2019001522 A1 CL 2019001522A1 CL 2019001522 A CL2019001522 A CL 2019001522A CL 2019001522 A CL2019001522 A CL 2019001522A CL 2019001522 A1 CL2019001522 A1 CL 2019001522A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- modified oligonucleotides
- kidney disease
- polycystic kidney
- polychistic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
SE PROPORCIONAN EN LA PRESENTE MÉTODOS PARA EL TRATAMIENTO DE UNA ENFERMEDAD POLIQUÍSTICA RENAL, QUE INCLUYE UNA ENFERMEDAD POLIQUÍSTICA RENAL DOMINANTE AUTOSÓMICA, MEDIANTE EL USO DE OLIGONUCLEÓTIDOS MODIFICADOS QUE SE DIRIGEN A MIR-17.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662430139P | 2016-12-05 | 2016-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019001522A1 true CL2019001522A1 (es) | 2019-10-25 |
Family
ID=60915610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019001522A CL2019001522A1 (es) | 2016-12-05 | 2019-06-04 | Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal. |
Country Status (18)
Country | Link |
---|---|
US (3) | US20200165606A1 (es) |
EP (1) | EP3548503A1 (es) |
JP (2) | JP7133553B2 (es) |
KR (1) | KR20190085951A (es) |
CN (1) | CN110036019A (es) |
AU (1) | AU2017370560C1 (es) |
BR (1) | BR112019011164A2 (es) |
CA (1) | CA3044896A1 (es) |
CL (1) | CL2019001522A1 (es) |
CO (1) | CO2019006234A2 (es) |
EA (1) | EA201991360A1 (es) |
IL (1) | IL266871A (es) |
MA (1) | MA46999A (es) |
MX (1) | MX2019006332A (es) |
PH (1) | PH12019501224A1 (es) |
TW (2) | TW202300647A (es) |
WO (1) | WO2018106566A1 (es) |
ZA (1) | ZA201903605B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA44836A (fr) | 2015-08-26 | 2018-07-04 | Univ Texas | Procédés de traitement du syndrome polykystique des reins |
JP7095893B2 (ja) * | 2017-02-21 | 2022-07-05 | 国立大学法人大阪大学 | アンチセンスオリゴ核酸 |
WO2020038968A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Microrna-134 biomarker |
TW202031268A (zh) * | 2018-11-13 | 2020-09-01 | 美商雷格勒斯治療公司 | 用於調節mir-10b 活性之微小rna 化合物及方法 |
IL311734A (en) * | 2021-10-08 | 2024-05-01 | Regulus Therapeutics Inc | Methods and compositions for the treatment of polycystic kidney disease |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2695608B1 (en) | 2006-10-03 | 2016-11-23 | Arbutus Biopharma Corporation | Lipid containing formulations |
MY156951A (en) | 2007-10-04 | 2016-04-15 | Santaris Pharma As | Micromirs |
AU2009221064B2 (en) * | 2008-03-07 | 2014-12-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
US20110189137A1 (en) * | 2009-11-11 | 2011-08-04 | Sanford-Burnham Medical Research Institute | Method for generation and regulation of ips cells and compositions thereof |
US20160362688A1 (en) * | 2014-02-12 | 2016-12-15 | Thomas Jefferson University | Compositions and methods of using microrna inhibitors |
MA44836A (fr) * | 2015-08-26 | 2018-07-04 | Univ Texas | Procédés de traitement du syndrome polykystique des reins |
-
2017
- 2017-12-04 CN CN201780074216.4A patent/CN110036019A/zh active Pending
- 2017-12-04 MA MA046999A patent/MA46999A/fr unknown
- 2017-12-04 EP EP17823261.7A patent/EP3548503A1/en active Pending
- 2017-12-04 MX MX2019006332A patent/MX2019006332A/es unknown
- 2017-12-04 WO PCT/US2017/064428 patent/WO2018106566A1/en unknown
- 2017-12-04 CA CA3044896A patent/CA3044896A1/en active Pending
- 2017-12-04 TW TW111120773A patent/TW202300647A/zh unknown
- 2017-12-04 JP JP2019529933A patent/JP7133553B2/ja active Active
- 2017-12-04 TW TW106142317A patent/TWI769197B/zh active
- 2017-12-04 US US16/463,041 patent/US20200165606A1/en not_active Abandoned
- 2017-12-04 AU AU2017370560A patent/AU2017370560C1/en active Active
- 2017-12-04 EA EA201991360A patent/EA201991360A1/ru unknown
- 2017-12-04 KR KR1020197016357A patent/KR20190085951A/ko active Search and Examination
- 2017-12-04 BR BR112019011164A patent/BR112019011164A2/pt unknown
-
2019
- 2019-05-26 IL IL266871A patent/IL266871A/en unknown
- 2019-05-31 PH PH12019501224A patent/PH12019501224A1/en unknown
- 2019-06-04 CL CL2019001522A patent/CL2019001522A1/es unknown
- 2019-06-05 ZA ZA2019/03605A patent/ZA201903605B/en unknown
- 2019-06-14 CO CONC2019/0006234A patent/CO2019006234A2/es unknown
-
2020
- 2020-09-25 US US16/948,620 patent/US20210095282A1/en not_active Abandoned
-
2022
- 2022-07-25 US US17/814,647 patent/US20230109466A1/en active Pending
- 2022-08-29 JP JP2022135567A patent/JP2022169726A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110036019A (zh) | 2019-07-19 |
AU2017370560C1 (en) | 2022-08-11 |
US20200165606A1 (en) | 2020-05-28 |
JP2022169726A (ja) | 2022-11-09 |
MA46999A (fr) | 2019-10-09 |
US20210095282A1 (en) | 2021-04-01 |
AU2017370560B2 (en) | 2021-11-18 |
ZA201903605B (en) | 2023-12-20 |
US20230109466A1 (en) | 2023-04-06 |
TW202300647A (zh) | 2023-01-01 |
KR20190085951A (ko) | 2019-07-19 |
BR112019011164A2 (pt) | 2019-10-08 |
IL266871A (en) | 2019-07-31 |
TWI769197B (zh) | 2022-07-01 |
CO2019006234A2 (es) | 2019-08-30 |
WO2018106566A1 (en) | 2018-06-14 |
MX2019006332A (es) | 2019-08-01 |
PH12019501224A1 (en) | 2019-09-23 |
EA201991360A1 (ru) | 2019-11-29 |
EP3548503A1 (en) | 2019-10-09 |
CA3044896A1 (en) | 2018-06-14 |
TW201821618A (zh) | 2018-06-16 |
JP2019536804A (ja) | 2019-12-19 |
JP7133553B2 (ja) | 2022-09-08 |
AU2017370560A1 (en) | 2019-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001522A1 (es) | Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal. | |
CL2016002667A1 (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
CL2017000285A1 (es) | Terapia combinada para el tratamiento de un paramixovirus | |
EA201691991A1 (ru) | Мультиспецифические антитела | |
CR20160257A (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
CR20150205S (es) | Almohada de viaje | |
DK3145934T3 (da) | Substituerede-6,8-dioxabicyclo[3.2.1]octan-2,3-diol-forbindelser som ASGPR-targeteringsmidler | |
CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
PE20150646A1 (es) | Metodos de tratamiento de una tauopatia | |
CL2017001661A1 (es) | Compuestos biciclicos fusionados para el tratamiento de una enfermedad. | |
CL2018003443A1 (es) | Tratamientos para el cancer. | |
CL2016002338A1 (es) | Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática . | |
SV2019005822A (es) | Metodos para tratar el cáncer de próstata | |
AR110378A1 (es) | Métodos para determinar el estado del cáncer colorrectal en una persona | |
CL2019001526A1 (es) | Métodos para el tratamiento de la enfermedad renal poliquística. | |
EP4268891A3 (en) | Compound for use in methods for treatment of polycystic kidney disease | |
MX2018003802A (es) | Formulacion de hipericina para el diagnostico fotodinamico. | |
CL2018000489A1 (es) | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona | |
JP2015043197A5 (es) | ||
CL2016002256A1 (es) | Un proceso mejorado para la preparación de exametazima | |
EA201700060A1 (ru) | Терапевтическое средство для кератоконъюнктивальных расстройств | |
CO2017000543A2 (es) | Lípido que comprende ácido docosapentaenoico | |
JP2016045189A5 (es) | ||
ECSP19015143A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
CR20140051A (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida |